Global Regenerative Medicines Market to Reach $87.03 Billion by 2030
Market Report Coverage - Regenerative Medicines
• Product – Tissue Engineering (Allogeneic Tissue, Autologous Tissue, Xenogeneic Tissue, and Synthetic Tissue), Stem Cells (Stem Cell Services and Stem Cell Therapies), and Cell ang Gene Therapy (Car-T Cell Therapy, Gene Therapy, Other Cell Therapies)
• Application – Orthopedic and Musculoskeletal, Oncology, Wound Care, Cardiology, Immunology, Dermatology, and Other Applications
• North America – U.S., and Canada
• Europe – Germany, U.K., France, Italy, Spain, Netherlands, Russia, and Rest-of-Europe
• Asia-Pacific – China, Japan, India, Australia, South Korea, Singapore, and Rest-of-Asia-Pacific
• Latin America – Brazil, Mexico, and Rest-of-Latin America
• Increasing Consolidation Among Healthcare Juggernauts
• Rising Number of Clinical Trials for Regenerative Therapies
• A Favorable Regulatory Environment to Accelerate Approvals and Market Entry
• A Rising Awareness for Stem Cell Therapeutics
• Lack of Reliable Vector Production for Cell and Gene Therapy
• Exorbitant Cost of Next-Generation Therapies
• Drug Approvals and Strong Pipeline of Cell and Gene Therapies
• Multiple Investments in Expansion of cGMP Units
• Innovations in Regenerative Medicine
Key Companies Profiled
AbbVie, Inc., Baxter International Inc., Becton, Dickinson and Company, Dendreon Pharmaceuticals LLC, F. Hoffmann-La Roche Ltd., FUJIFILM Holdings Corporation, Gilead Sciences, Inc., Integra LifeSciences Holdings Corporation, Johnson & Johnson, Medtronic plc, Mesoblast Ltd., Novartis International A.G., NuVasive, Inc., Organogenesis Holdings, Inc., Smith & Nephew plc, Stryker Corporation, Vericel Corporation, and Zimmer Biomet Holdings, Inc.
Key Questions Answered in this Report: • What are the major market drivers, challenges, and opportunities and their respective impacts on the global regenerative medicines market?
• What is the potential impact of advancement in therapeutics among emerging segments of the global regenerative medicines market?
• What is the current market demand along with future demand for the global regenerative medicines market?
• What are the key regulatory hurdles for industry players looking to enter this highly dynamic market?
• What are the key development strategies that are implemented by the major players in order to sustain the competitive market?
• How is each of the segments of the market expected to grow during the forecast period from 2020 to 2030 based on each segment? Following are the segments:
o Regions, namely, North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World (RoW)
• Who are the leading players with significant offerings to the global regenerative medicines market? What is the expected market share for each of these leading players?
• Which emerging companies are anticipated to be highly disruptive in the future, and what are their key strategies for sustainable growth in the global regenerative medicines market?
• How is the underlying cell and gene therapy segment pushing the boundaries of regenerative medicine across the world? What are the next-generation therapies within this segment?
Healthcare experts have found cell and gene therapy to be one of the most rapidly evolving and dynamic markets, and the global market for regenerative medicines is predicted to grow at a CAGR of 13.99% over the forecast period of 2020-2030. The market is driven by certain factors, including increasing consolidation among healthcare juggernauts, rising number of clinical trials for regenerative therapies, a favorable regulatory environment to accelerate approvals and market entry, and rising awareness for stem cell therapeutics, that are fueling the growth of the global regenerative medicines market.
Regenerative medicine is challenging the current healthcare practices by targeting the treatment of the root causes of disease and disorders, transforming it into an incredibly exciting space. However, these advancements have not come without significant challenges and uncertainties, which will also further need to be overcome to realize the full potential of regenerative medicine.
Cell and gene therapies, under the regenerative umbrella, are slowly and steadily becoming a healthcare standard, particularly in developed regions such as the U.S. and Europe, where already established markets for tissue engineering and stem cell have largely been responsible for driving the global regenerative medicine phenomenon. Cell and gene therapies, though advancing at a rapid pace, have primarily been targeted for hematological malignancies. However, the same potential has not been replicated in solid tumor applications, consequently creating demand for cell therapies focusing on solid tumors. As a result, the industry is now moving toward the research and subsequent clinical translation of next-generation therapies, led by natural killer (NK) cells, which offer a viable option for solid tumors as well. Such trends are consistently propelling the industry toward realizing the true potential of precision medicine.
Within the research report, the market is segmented on the basis of products, applications, and region. Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.
The global regenerative medicines market is currently witnessing several developments, primarily aimed toward bringing new products to support clinicians for the treatment of life-threatening disorders.Major manufacturers of regenerative medicine products are actively involved in undertaking significant business strategies in order to translate success in research and development into the commercial clinical setting.
Although tissue engineering and stem cells remain the dominating product segments, the advent of cell and gene therapy has revolutionized the regenerative medicine phenomenon, moving it more toward the precision medicine space.
On the basis of region, North America holds the largest share of the regenerative medicines market due to a high number of active advanced therapeutic medicinal product trials, massive government funding, expansion activities by major companies, and an overall high adoption rate for advancing therapies. Apart from this, the Asia-Pacific region is anticipated to grow at the fastest CAGR during the forecast period, 2020-2030.
Countries Covered • North America
• South Korea
• Latin America
• Rest-of-Latin America
Our reports have been used by over 10K customers, including:
306 pages •
By Global Industry Analysts
• May 2021
Global Cell Harvesting Market to Reach $359.2 Million by 2026
Cell harvesting is a next-generation technique that involves collection of stem cells from the culture media for R&D and therapeutic applications. Growth in the global market is spurred by of increasing investments...
The global single-use assemblies market is projected to reach USD 6.3 billion by 2026 from USD 2.2 billion in 2021, at a CAGR of 23.3% during the forecast period. The growth of the single-use assemblies market can primarily be attributed to the major advantages of single-use technologies as compared to traditional stainless-steel assemblies,...
120 pages •
By Infiniti Research Limited
• Jun 2021
Global Biosimilars Market 2021-2025 The analyst has been monitoring the biosimilars market and it is poised to grow by $ 31.40 bn during 2021-2025, progressing at a CAGR of 24.77% during the forecast period. Our report on the biosimilars market provides a holistic analysis, market size and forecast, trends, growth drivers,...
175 pages •
By The Business Research Company
• Jun 2021
Major players in the enzymes market are Sanofi, AbbVie Inc., Alexion Pharmaceuticals Inc, Horizon Pharma, Allergan plc, Pfizer Inc., Vivus, Digestive Care, Leadiant Biosciences, and Roche Holdings AG The global enzymes market is expected to grow from $7.81 billion in 2020 to $8.9 billion in 2021 at a compound annual growth rate (CAGR)...
Apoptosis Regulator BAX - Drugs In Development, 2021 Summary Apoptosis Regulator BAX (Bcl 2 Like Protein 4 or BCL2L4 or BAX) - Apoptosis regulator BAX or bcl-2-like protein 4 is a protein is encoded by the BAX gene. It accelerates programmed cell death by antagonizing the apoptosis repressor BCL2....
The Global Biologics CDMO Market was valued at USD 9.93 billion in 2020 and is expected to reach USD 18.63 billion by 2026, registering a CAGR of 10.87% during the forecast period (2021-2026). The CMO/CDMO service sector is uniquely positioned to address some of the challenges that drug developers are facing amid the COVID-19 pandemic....
The Formulation Development Outsourcing market was valued at approximately USD 8,055 million in 2020 and is expected to witness a revenue of USD 12,650 million in 2026, with a CAGR of 7.2% over the forecast period. The rapidly evolving threat of COVID-19 is impacting lives, communities, businesses, and industries around the world. The...
The Global Infectious Vaccines Partnering Terms and Agreements 2014 to 2021: Deal trends, players and financials report provides a detailed understanding and analysis of how and why companies enter infectious vaccines partnering deals. The majority of deals are development stage whereby the licensee obtains a right...
“Axial spondyloarthritis - Pipeline Insight, 2021,” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Axial spondyloarthritis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route...
Interferon Alpha (IFNA) - Drugs in Development, 2021 Summary Interferon Alpha (IFNA) - Drugs in Development, 2021 provides in depth analysis on Interferon Alpha (IFNA) targeted pipeline therapeutics. The report provides comprehensive information complete with Analysis by Indications, Stage of Development,...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.